By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


H. Lundbeck A/S 

Ottiliavej 9

Valby  Copenhagen  DK-2500  Denmark
Phone: 45-3630-1311 Fax: 45 3630 1940



Forest  Forest's partner for many of the drug compounds that we develop, manufacture and market in the U.S. for central nervous system disorders, including Lexapro.

Company News
H. Lundbeck A/S (LUN.CO) Throws in the Towel on Alzheimer's Pill, Giving Leeway to Rival Axovant (AXON) 2/8/2017 5:27:55 AM
Ossianix Release: Company Receives Milestone Payment From H. Lundbeck A/S (LUN.CO) For Blood-Brain Barrier (BBB) Antibody Delivery Technology 1/26/2017 9:18:24 AM
Otsuka Pharmaceutical Development & Commercialization, Inc. And H. Lundbeck A/S (LUN.CO) Present Data At ACNP Annual Meeting On Long-Acting Injectable Aripiprazole As A Potential Maintenance Treatment For Bipolar I Disorder 12/7/2016 9:46:21 AM
H. Lundbeck A/S (LUN.CO)'s Phase III Data Crushes Hope for Alzheimer’s Once Again 9/23/2016 5:45:12 AM
Patient Groups Rank Lundbeck US First In Corporate Reputation Among Top Pharmaceutical Companies 4/7/2016 11:27:42 AM
H. Lundbeck A/S (LUN.CO) Falls After FDA Rejects Brintellix Label Expansion 3/29/2016 6:02:46 AM
Agilis Biotherapeutics Names Former H. Lundbeck A/S (LUN.CO) Executive, Christopher J. Silber, MD, As Chief Medical Officer 1/25/2016 7:32:12 AM
H. Lundbeck A/S (LUN.CO) Release: Largest Prospective Study Evaluating The Effect Of Vigabatrin On Vision 11/25/2015 10:38:49 AM
H. Lundbeck A/S (LUN.CO): Experts Call For Urgent Action To Better Diagnose Severe Form Of Bipolar I Disorder, Which Is Costing Healthcare Economies Billions1,2 8/31/2015 11:04:38 AM
H. Lundbeck A/S (LUN.CO) Slashing 1,000 Employees as Company Faces Declining Revenue Due to Generic Competition 8/19/2015 5:53:09 AM